450 related articles for article (PubMed ID: 34942494)
1. Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.
Desai A; Abdayem P; Adjei AA; Planchard D
Lung Cancer; 2022 Jan; 163():96-106. PubMed ID: 34942494
[TBL] [Abstract][Full Text] [Related]
2. 'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.
Verma S; Breadner D; Raphael J
Curr Oncol; 2023 Apr; 30(4):4329-4350. PubMed ID: 37185443
[TBL] [Abstract][Full Text] [Related]
3. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
[TBL] [Abstract][Full Text] [Related]
4. TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).
Parisi C; Mahjoubi L; Gazzah A; Barlesi F
Cancer Treat Rev; 2023 Jul; 118():102572. PubMed ID: 37230055
[TBL] [Abstract][Full Text] [Related]
5. Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody-Drug Conjugates.
Belluomini L; Sposito M; Avancini A; Insolda J; Milella M; Rossi A; Pilotto S
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001628
[TBL] [Abstract][Full Text] [Related]
6. Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
Peters S; Loi S; André F; Chandarlapaty S; Felip E; Finn SP; Jänne PA; Kerr KM; Munzone E; Passaro A; Pérol M; Smit EF; Swanton C; Viale G; Stahel RA
Ann Oncol; 2024 Jul; 35(7):607-629. PubMed ID: 38648979
[TBL] [Abstract][Full Text] [Related]
7. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles.
Fenton MA; Tarantino P; Graff SL
Curr Oncol; 2023 Nov; 30(12):10211-10223. PubMed ID: 38132377
[TBL] [Abstract][Full Text] [Related]
8. Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress.
Rosner S; Valdivia A; Hoe HJ; Murray JC; Levy B; Felip E; Solomon BJ
Am Soc Clin Oncol Educ Book; 2023 May; 43():e389968. PubMed ID: 37163707
[TBL] [Abstract][Full Text] [Related]
9. Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: Emergence of a Novel Therapeutic Class.
Marks JA; Wilgucki M; Liu SV; Reuss JE
Curr Oncol Rep; 2022 Dec; 24(12):1829-1841. PubMed ID: 36197593
[TBL] [Abstract][Full Text] [Related]
10. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Rudin CM; Pietanza MC; Bauer TM; Ready N; Morgensztern D; Glisson BS; Byers LA; Johnson ML; Burris HA; Robert F; Han TH; Bheddah S; Theiss N; Watson S; Mathur D; Vennapusa B; Zayed H; Lally S; Strickland DK; Govindan R; Dylla SJ; Peng SL; Spigel DR;
Lancet Oncol; 2017 Jan; 18(1):42-51. PubMed ID: 27932068
[TBL] [Abstract][Full Text] [Related]
11. Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors.
Nelson BE; Meric-Bernstam F
Annu Rev Med; 2024 Jan; 75():31-48. PubMed ID: 37758237
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.
Nagayama A; Ellisen LW; Chabner B; Bardia A
Target Oncol; 2017 Dec; 12(6):719-739. PubMed ID: 29116596
[TBL] [Abstract][Full Text] [Related]
13. Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.
Domb C; Garcia JA; Barata PC; Mendiratta P; Rao S; Brown JR
Ther Adv Urol; 2024; 16():17562872241249073. PubMed ID: 38779496
[TBL] [Abstract][Full Text] [Related]
14. Antibody Drug Conjugates in Lung Cancer.
Merle G; Friedlaender A; Desai A; Addeo A
Cancer J; 2022 Nov-Dec 01; 28(6):429-435. PubMed ID: 36383905
[TBL] [Abstract][Full Text] [Related]
15. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
16. Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach.
Marks S; Naidoo J
Lung Cancer; 2022 Jan; 163():59-68. PubMed ID: 34923203
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Resistance to Antibody-Drug Conjugates.
Khoury R; Saleh K; Khalife N; Saleh M; Chahine C; Ibrahim R; Lecesne A
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298631
[TBL] [Abstract][Full Text] [Related]
18. Antibody-Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond-A 2023 Review.
Xiao T; Ali S; Mata DGMM; Lohmann AE; Blanchette PS
Curr Oncol; 2023 Jul; 30(7):6447-6461. PubMed ID: 37504334
[TBL] [Abstract][Full Text] [Related]
19. Antibody-drug conjugates in solid tumors: a look into novel targets.
Criscitiello C; Morganti S; Curigliano G
J Hematol Oncol; 2021 Jan; 14(1):20. PubMed ID: 33509252
[TBL] [Abstract][Full Text] [Related]
20. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]